Insider Selling: Vaxcyte, Inc. (NASDAQ:PCVX) COO Sells $689,760.00 in Stock

Vaxcyte, Inc. (NASDAQ:PCVX) COO Jim Wassil sold 8,000 shares of Vaxcyte stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $86.22, for a total value of $689,760.00. Following the transaction, the chief operating officer now directly owns 205,695 shares of the company’s stock, valued at $17,735,022.90. This trade represents a 3.74 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Jim Wassil also recently made the following trade(s):

• On Thursday, January 2nd, Jim Wassil sold 8,000 shares of Vaxcyte stock. The stock was sold at an average price of $83.66, for a total value of $669,280.00.
• On Monday, December 2nd, Jim Wassil sold 8,000 shares of Vaxcyte stock. The stock was sold at an average price of $92.49, for a total value of $739,920.00.

Vaxcyte Price Performance

NASDAQ PCVX opened at $89.01 on Friday. Vaxcyte, Inc. has a 12 month low of $58.10 and a 12 month high of $121.06. The company has a 50-day moving average of $87.27 and a 200-day moving average of $94.42. The company has a market cap of $11.09 billion, a P/E ratio of -19.35 and a beta of 0.98.

Vaxcyte (NASDAQ:PCVX) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($0.83) EPS for the quarter, beating analysts’ consensus estimates of ($1.10) by $0.27. During the same quarter last year, the company posted ($0.91) EPS. As a group, equities research analysts anticipate that Vaxcyte, Inc. will post -4.21 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Blue Trust Inc. increased its stake in shares of Vaxcyte by 33.5% during the 3rd quarter. Blue Trust Inc. now owns 371 shares of the company’s stock valued at $42,000 after acquiring an additional 93 shares during the last quarter. Nisa Investment Advisors LLC grew its holdings in shares of Vaxcyte by 5.2% during the 3rd quarter. Nisa Investment Advisors LLC now owns 2,209 shares of the company’s stock worth $252,000 after purchasing an additional 110 shares during the period. CIBC Asset Management Inc grew its holdings in shares of Vaxcyte by 3.6% during the 3rd quarter. CIBC Asset Management Inc now owns 3,136 shares of the company’s stock worth $358,000 after purchasing an additional 110 shares during the period. Riverview Trust Co purchased a new stake in shares of Vaxcyte during the 3rd quarter worth about $27,000. Finally, Smartleaf Asset Management LLC grew its holdings in shares of Vaxcyte by 188.4% during the 4th quarter. Smartleaf Asset Management LLC now owns 398 shares of the company’s stock worth $33,000 after purchasing an additional 260 shares during the period. Institutional investors and hedge funds own 96.78% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vaxcyte in a research note on Wednesday, November 6th. The Goldman Sachs Group assumed coverage on shares of Vaxcyte in a research note on Friday, December 20th. They issued a “buy” rating and a $135.00 target price for the company. Finally, Needham & Company LLC reissued a “buy” rating and issued a $140.00 target price on shares of Vaxcyte in a research note on Wednesday, November 6th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $145.71.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.